Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00966238 · ClinicalTrials.gov registry record · Phase 2
Safety and Immunogenicity of VAX125 Influenza Vaccine in Community-living Adults >= 65 Years of Age
A Phase 2 study, sponsored by VaxInnate Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT00966238 is a Phase 2 study that has completed, run by VaxInnate Corporation. The registered enrollment target is 120 participants.
The verdict
NCT00966238, a Phase 2 study, has completed, sponsored by VaxInnate Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
A multi-center, open-label, escalating dose-ranging study to assess the safety, reactogenicity, and immunogenicity of four different VAX125 vaccine doses; 0.5 µg, 1.0 µg, 2.0 µg, or 3.0 µg, delivered i.m. as a single dose vaccination on Day 0. Hypothesis: VAX125 is safe and immunogenic at one or more of the doses tested.
Interventions
- BIOLOGICAL VAX125
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2009-09 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00966238
The ClinicalTrials.gov registry entry for NCT00966238 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VaxInnate Corporation, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VAX125 is the first listed.
NCT00966238 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00966238 about?
NCT00966238 is a clinical study titled "Safety and Immunogenicity of VAX125 Influenza Vaccine in Community-living Adults >= 65 Years of Age". A multi-center, open-label, escalating dose-ranging study to assess the safety, reactogenicity, and immunogenicity of four different VAX125 vaccine doses; 0.5 µg, 1.0 µg, 2.0 µg, or 3.0 µg, delivered i.m. as a single dose vaccination on Day 0. Hypothesis: VAX125 is safe and immunogenic at one or mor...
What is the current status of trial NCT00966238?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2009-09. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00966238?
The interventions under investigation include: VAX125 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00966238?
This trial is sponsored by VaxInnate Corporation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.